AR and triple-negative breast carcinoma: In a previous study, RUNX1 was found to collaborate with the androgen receptor in triple-negative breast cancer CSCs to promote cancer recurrence after chemotherapy, whereas inhibition of RUNX1 transcriptional activity reduced expression of CSC marker genes [23].